Cardiff Oncology
Biotechnology ResearchView the employees at
Cardiff Oncology-
Jose Altamirano Accountant at Cardiff Oncology
-
Chula Vista, California, United States
-
Rising Star
Kristin Echevarria Executive Assistant at Trovagene, Inc.-
San Diego, California, United States
-
Rising Star
Maya Ridinger, PhD Director of Research Development at Cardiff Oncology (former Trovagene)-
San Diego, California, United States
-
Top 10%
Divora Yemane Senior Research Associate at Cardiff Oncology-
San Diego, California, United States
-
Rising Star
Robert Milford Associate Director, Clinical Operations at Cardiff Oncology-
Los Angeles, California, United States
-
Rising Star
Overview
Cardiff Oncology is a clinical-stage biotechnology company, headquartered in San Diego, CA, leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers. Our lead asset is onvansertib, a PLK1 inhibitor being evaluated in combination with standard-of-care (SoC) therapeutics in clinical programs targeting indications such as KRAS/NRAS-mutated metastatic colorectal cancer (mCRC) and metastatic pancreatic ductal adenocarcinoma (mPDAC), as well as in investigator-initiated trials in triple negative breast cancer (TNBC) and small cell lung cancer (SCLC). These programs and Cardiff's broader development strategy are designed to target tumor vulnerabilities in order to overcome treatment resistance and deliver superior clinical benefit compared to the SoC alone. For more information, please visit https://www.cardiffoncology.com.
-